
|Articles|October 18, 2021
Daily Medication Pearl: Lurasidone Hydrochloride (Latuda) for Schizophrenia
Author(s)Saro Arakelians, PharmD
The efficacy of Latuda in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin type 2 receptor antagonism.
Advertisement
Medication Pearl of the Day: Lurasidone Hydrochloride (Latuda)
Indication: Latuda is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and adolescents, depressive episode associated with bipolar I disorder in adults and pediatric patients as monotherapy, and depressive episode associated with bipolar I disorder in adults as adjunctive therapy with lithium or valproate.
Insight:
- Dosing: Depending on the diagnosis, may start from 20 mg up to 160 mg per day.
- Dosage form: Tablets 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.
- Adverse events (AEs): Common AEs associated with Latuda are somnolence, akathisia, extrapyramidal symptoms, nausea, rhinitis, weight increase, and insomnia.
- Mechanism of action: Its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin type 2 receptor antagonism.
- Manufacturer: Sunovion
Sources:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
4
FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea
5






































































































